Variant AAV Capsids Enhance Retinal Cell Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy vectors face challenges in optimizing viral cell tropism, particularly for delivering therapeutic genes to the retina, necessitating improved virions with enhanced specificity and delivery efficiency.
Innovation Solution
Development of recombinant adeno-associated virus (AAV) virions with modified AAV capsid proteins, specifically variant AAV capsid proteins containing amino acid substitutions, to enhance binding and transduction of retinal cells, including photoreceptors, ganglion cells, and retinal pigment epithelium cells, via intravitreal injection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional AAV capsid proteins are used, then general gene delivery capability is maintained, but delivery efficiency to retinal cells is insufficient
Solution Approach 1:
The patent applies local quality by introducing specific amino acid substitutions at defined positions (570-579) in the AAV capsid protein sequence. These localized modifications create capsid variants with enhanced affinity for retinal cell surface receptors, thereby improving delivery efficiency to specific retinal cells while maintaining overall capsid structure and function.
Solution Approach 2:
The patent employs parameter changes by systematically varying amino acid residues at positions 570-579 of the capsid protein to optimize binding properties. Through screening different amino acid substitutions, the invention identifies variants with improved transduction efficiency for retinal cells, effectively tuning the capsid's interaction parameters with target cell surfaces.
2Productivity
If AAV virions are modified to enhance retinal cell transduction, then transduction efficiency improves, but capsid structure stability may be compromised
Solution Approach 1:
The modifications are confined to a specific region (amino acid positions 570-579) of the capsid protein, allowing enhancement of retinal cell binding affinity without disrupting the overall capsid architecture. This localized modification strategy preserves capsid stability while achieving improved transduction efficiency.
Solution Approach 2:
The patent introduces multiple amino acid substitutions within a limited sequence region to achieve sufficient binding enhancement without excessive modification that could compromise structural integrity. The substitutions are optimized to provide adequate transduction improvement while maintaining capsid stability.
Data Source
AI summary
Provided are variant adeno-associated virus (AAV) capsid proteins and recombinant AAV virions having one or more variant AAV capsid proteins. Also provided are compositions and methods for the use of the recombinant AAV virions, such as for the treatment or prophylaxis of a disease or disorder.